美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Innovent Biologics Inc.

39.75

0.0000

成交量：- -

成交額：- -

市值：170.93億

市盈率：-4,835.77

高：39.75

開：39.75

低：39.75

收：39.75

52周最高：52.00

52周最低：19.15

股本：4.30億

流通股本：4.30億

量比：1.86

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):-0.0082

每股收益(LYR):-0.0080

淨資產收益率：8.43%

總資產收益率：2.65%

市淨率：8.18

市盈率(LYR):-4,989.96

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

信達生物合作伙伴Ollin宣佈IBI324頭對頭法瑞西單抗臨牀Ib期研究積極頂線數據，顯示更優療效

首個國產抗CTLA-4單抗：信達生物達伯欣®(伊匹木單抗N01注射液)獲國家藥品監督管理局批准上市

登頂《Nature》主刊 | 信爾美®（瑪仕度肽注射液，GCG/GLP-1雙靶減重降糖藥物）兩項III期臨牀研究結果背靠背同步發表

瑪仕度肽中國青少年肥胖人羣Ib期研究達主要終點展現出顯著減重療效和代謝獲益

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/IVBIY"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IVBIY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IVBIY\",,,,,undefined,":{"symbol":"IVBIY","market":"US","secType":"STK","nameCN":"Innovent Biologics Inc.","latestPrice":39.75,"timestamp":1771621200000,"preClose":39.75,"halted":0,"volume":0,"delay":15,"changeRate":0,"floatShares":430000000,"shares":430000000,"eps":-0.00822,"marketStatus":"休市中","change":0,"latestTime":"02-20 16:00:00 EST 延時","open":39.75,"high":39.75,"low":39.75,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.00822,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":7,"adr":0,"adrRate":4,"exchange":"PINK LIMITED","adjPreClose":39.75,"volumeRatio":1.8633563519954686},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IVBIY\",,,,,undefined,":{"symbol":"IVBIY","floatShares":430000000,"roa":"2.65%","roe":"8.43%","lyrEps":-0.007966,"volumeRatio":1.8633563519954686,"shares":430000000,"dividePrice":0,"high":39.75,"amplitude":0,"preClose":39.75,"low":39.75,"week52Low":19.15,"pbRate":"8.18","psRate":"10.32","week52High":52,"institutionHeld":0,"latestPrice":39.75,"eps":-0.00822,"divideRate":0,"volume":0,"delay":15,"ttmEps":-0.00822,"open":39.75,"prevYearClose":41.75,"prevWeekClose":39.75,"prevMonthClose":39.75,"prevQuarterClose":41.75,"fiveDayClose":39.75,"twentyDayClose":41.8,"sixtyDayClose":45.184},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IVBIY\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-08-28","symbol":"IVBIY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤前","type":"earning","dateTimestamp":1724817600000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IVBIY\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IVBIY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4483,"buy":0.4483,"hold":0.1034,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.4483,"analysts":29,"updateTime":1767848400000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IVBIY\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2602348564","title":"信達生物合作伙伴Ollin宣佈IBI324頭對頭法瑞西單抗臨牀Ib期研究積極頂線數據，顯示更優療效","url":"https://stock-news.laohu8.com/highlight/detail?id=2602348564","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602348564?lang=zh_tw&edition=fundamental","pubTime":"2026-01-09 08:00","pubTimestamp":1767916800,"startTime":"0","endTime":"0","summary":"OLN324相较法瑞西单抗在视网膜积液消退的速度和幅度上展现出的差异极具说服力，并具有明确的临床意义。\" Ollin Biosciences联合创始人兼首席执行官Jason Ehrlich医学博士表示：\"OLN324是首个也是目前唯一一个在随机、头对头临床研究中显示出解剖学疗效优于市场领先药物法瑞西单抗的治疗方案。在安全性方面，OLN324显示出良好的安全性特征。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4859017_ZH59017_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["01801","LU2097828631.EUR","BK1161","BK1583","LU0502904849.HKD","BK1589","LU2097828557.USD","LU2488822045.USD","LU0455707207.USD","LU2242644610.SGD","BK4139","LU1969619763.USD","LU2328871848.SGD","IVBIY","LU2097828714.EUR","HK0000165453.HKD","LU2097828474.EUR","LU2097828805.USD"],"gpt_icon":0},{"id":"2594076236","title":"首個國產抗CTLA-4單抗：信達生物達伯欣®(伊匹木單抗N01注射液)獲國家藥品監督管理局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2594076236","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594076236?lang=zh_tw&edition=fundamental","pubTime":"2025-12-25 17:59","pubTimestamp":1766656740,"startTime":"0","endTime":"0","summary":"达伯欣的新药上市申请获中国国家药品监督管理局批准，联合达伯舒用于可手术切除的IIB-III期微卫星高度不稳定型或错配修复缺陷结肠癌患者的新辅助治疗。安全性方面，伊匹木单抗N01联合信迪利单抗组相较直接手术组未显著增加额外的安全性风险。我们很高兴在信达生物高质量高效的临床开发推动下，达伯欣  作为中国首个本土创新的抗CTLA-4抑制剂成功获批上市，为中国可手术切除MSI-H/dMMR结肠癌患者提供新的治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4853695_ZH53695_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2097828474.EUR","LU2328871848.SGD","LU2097828714.EUR","LU0502904849.HKD","LU0455707207.USD","LU2097828805.USD","LU2242644610.SGD","BK1583","LU2097828557.USD","LU2097828631.EUR","BK1161","HK0000165453.HKD","LU1969619763.USD","BK4139","BK1589","IVBIY","LU2488822045.USD","01801"],"gpt_icon":0},{"id":"2592442959","title":"登頂《Nature》主刊 | 信爾美®（瑪仕度肽注射液，GCG/GLP-1雙靶減重降糖藥物）兩項III期臨牀研究結果背靠背同步發表","url":"https://stock-news.laohu8.com/highlight/detail?id=2592442959","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592442959?lang=zh_tw&edition=fundamental","pubTime":"2025-12-18 08:00","pubTimestamp":1766016000,"startTime":"0","endTime":"0","summary":"此次论文通过《自然》加速预览机制得以快速上线，再次印证国际顶级期刊对于玛仕度肽两项重磅研究的认可。信达生物制药集团综合管线首席研发官钱镭博士表示：\"信尔美是全球首个获批上市的GCG/GLP-1双靶药物，目前减重和糖尿病适应症均已获批。继其减重注册研究今年五月份发表于《新英格兰杂志》后，本次两项降糖注册研究DREAMS-1和DREAMS-2的成果再次以背靠背形式同步登上《自然》杂志，并以加速预览形式发表。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4849560_ZH49560_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["III","LU2097828714.EUR","LU2097828557.USD","BK1589","LU2242644610.SGD","LU2097828631.EUR","01801","BK4134","LU2097828474.EUR","BK1583","LU2097828805.USD","LU0502904849.HKD","LU0455707207.USD","BK1161","BK4139","GLP","LU2488822045.USD","LU1969619763.USD","LU2328871848.SGD","HK0000165453.HKD","BK4590","BK4144","IVBIY"],"gpt_icon":0},{"id":"2590526115","title":"瑪仕度肽中國青少年肥胖人羣Ib期研究達主要終點展現出顯著減重療效和代謝獲益","url":"https://stock-news.laohu8.com/highlight/detail?id=2590526115","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590526115?lang=zh_tw&edition=fundamental","pubTime":"2025-12-12 08:00","pubTimestamp":1765497600,"startTime":"0","endTime":"0","summary":"目前国内没有任何批准用于儿童、青少年的减重药物，玛仕度肽青少年肥胖的III期注册临床将于近期启动。此项研究结果令人倍感鼓舞，表明玛仕度肽为中国青少年肥胖人群提供了一种兼具强效减重疗效与良好安全性的全新治疗方案。玛仕度肽已在多项临床研究中展现出优秀的减重和降糖疗效，以及降低腰围、血脂、血压、血尿酸、肝酶及肝脏脂肪含量，以及改善胰岛素敏感性，带来多重代谢获益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4844686_ZH44686_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2097828714.EUR","BK1161","BMI","01801","BK4157","LU1969619763.USD","LU2328871848.SGD","BK4139","LU2488822045.USD","HK0000165453.HKD","BK1589","LU2097828805.USD","LU0502904849.HKD","LU2097828557.USD","LU2097828474.EUR","BK1583","OXM","LU0455707207.USD","IVBIY","LU2097828631.EUR","LU2242644610.SGD","BK4202"],"gpt_icon":0}],"pageSize":4,"totalPage":4,"pageCount":1,"totalSize":16,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/IVBIY\",params:#limit:6,delay:false,,,undefined,":[]}}